Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Aug;60(3):427-428.
doi: 10.1111/apt.18136. Epub 2024 Jun 24.

Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease: Authors' reply

Tsz Hong Yiu  1 , Yanna Ko  2   3 , Aviv Pudipeddi  3 , Patrizia Natale  1   4   5 , Rupert W Leong  3
Affiliations
Comment

Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease: Authors' reply

Tsz Hong Yiu et al. Aliment Pharmacol Ther. 2024 Aug.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Rao V, Chen G, Koh E, Segal J. Letter: persisting with persistence—a caution as an outcome measure in inflammatory bowel disease. Aliment Pharmacol Ther. 2024;60:425–426.
    1. Yiu TH, Ko Y, Pudipeddi A, Natale P, Leong RW. Meta‐analysis: persistence of advanced therapies in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;59(11):1312–1334.
    1. Pudipeddi A, Fung C, Christensen B, Bryant RV, Subramaniam K, Chetwood J, et al. Knowledge and attitudes towards the use of histological assessments in ulcerative colitis by gastroenterologists vs pathologists. World J Gastroenterol. 2023;29(2):378–389.
    1. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. International Organization for the Study of IBD. STRIDE‐II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat‐to‐target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583.
    1. Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, et al. Review article: consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11–12):1037–1053.

MeSH terms

Substances

LinkOut - more resources